The fiscal year 2025 witnessed a dramatic recalibration at the apex of the pharmaceutical industry’s sales leaderboard, characterized by a dual narrative of enduring oncology dominance and the meteoric rise of metabolic innovations. While Merck’s oncology powerhouse, Keytruda, steadfastly maintained its position as the top-selling brand, the landscape beneath it was profoundly reshaped as Eli Lilly’s tirzepatide (marketed as Mounjaro and Zepbound) and Novo Nordisk’s semaglutide (Ozempic and Wegovy) surged past it at the molecular level, signaling a profound shift in market dynamics. This unprecedented reshuffle, detailed in comprehensive industry analyses, underscored a period of intense innovation and competitive evolution within the global pharmaceutical sector.
The Ascendancy of GLP-1 Agonists: Reshaping the Metabolic Landscape
The most compelling story of FY2025 was undoubtedly the explosive growth of glucagon-like peptide-1 (GLP-1) receptor agonists, spearheaded by Eli Lilly’s tirzepatide and Novo Nordisk’s semaglutide. These drugs, initially approved for type 2 diabetes, have revolutionized the treatment of obesity, driving unprecedented sales figures and fundamentally altering therapeutic paradigms. Mounjaro, Lilly’s tirzepatide for diabetes, recorded an astounding $22.965 billion in FY2025, nearly doubling its FY2024 sales with a remarkable 99.0% year-over-year growth. Its sibling, Zepbound, specifically approved for weight management, demonstrated even more explosive growth, rocketing to $13.542 billion from $4.926 billion in FY2024, marking a staggering 174.9% increase.
Novo Nordisk’s semaglutide franchise also posted robust numbers. Ozempic, the diabetes formulation, achieved $19.206 billion in sales, growing 5.6% year-over-year. Wegovy, its weight-loss counterpart, saw a substantial 35.9% increase, reaching $11.955 billion. Collectively, the molecular sales of tirzepatide ($36.507 billion) and semaglutide ($31.161 billion) significantly surpassed Keytruda’s brand sales, illustrating the immense market potential and clinical demand for these therapies.
The profound impact of GLP-1 agonists extends beyond mere sales figures. These drugs represent a paradigm shift in how chronic metabolic diseases are managed, offering efficacy previously unseen in the treatment of obesity and providing substantial benefits for glycemic control in diabetes. Experts suggest that the success of these molecules is driven by a confluence of factors: high unmet medical need in obesity, compelling clinical data demonstrating significant weight loss and cardiovascular benefits, and growing public awareness. This success is likely to spur continued investment in metabolic research and development, with numerous other companies now vying to enter this lucrative and impactful therapeutic area. Executives from both Eli Lilly and Novo Nordisk have consistently emphasized their commitment to expanding access and exploring further therapeutic indications for these groundbreaking compounds, acknowledging their transformative potential for global public health.
Keytruda’s Unwavering Dominance in Oncology
Despite the spectacular rise of the GLP-1s, Merck’s Keytruda (pembrolizumab) firmly held its position as the leading pharmaceutical brand globally, generating $31.680 billion in FY2025, an increase of 7.5% from $29.482 billion in FY2024. This continued growth underscores the enduring power of immuno-oncology and Keytruda’s foundational role across numerous cancer types. Its broad approval across various indications, including melanoma, lung cancer, head and neck cancer, and renal cell carcinoma, among others, has cemented its status as a cornerstone of modern cancer treatment.
The oncology landscape, however, remains fiercely competitive and dynamic. Bristol Myers Squibb’s Opdivo (nivolumab), another leading PD-1 inhibitor, also showed steady growth, reaching $10.049 billion, an 8.0% increase. Other significant oncology drugs demonstrated strong performances: Johnson & Johnson’s Darzalex (daratumumab) for multiple myeloma grew by 23.0% to $14.351 billion, highlighting its continued expansion and clinical utility. AstraZeneca’s Tagrisso (osimertinib), a targeted therapy for lung cancer, posted a 10.2% increase to $7.254 billion, while its counterpart Imfinzi (durvalumab) grew an impressive 28.5% to $6.063 billion. Eli Lilly’s breast cancer treatment Verzenio (abemaciclib) saw a 7.8% rise to $5.723 billion, and Novartis’s Kisqali (ribociclib), also for breast cancer, surged by 57.7% to $4.783 billion, indicating robust adoption and efficacy in their respective niches.
However, not all oncology drugs maintained upward trajectories. Older blockbusters like Bristol Myers Squibb’s Revlimid (lenalidomide) experienced a sharp decline, plummeting by 48.9% to $2.951 billion, largely due to generic competition following patent expirations. Pfizer’s Ibrance (palbociclib) also saw a 5.6% decrease to $4.122 billion, facing competitive pressures. These shifts emphasize the continuous need for innovation and pipeline replenishment in oncology, as new therapies emerge and older ones face patent cliffs and increased competition.
Immunologicals: A Sustained Engine of Growth
Beyond the headline battles, the FY2025 data revealed a crucial trend: the sustained expansion of scaled specialty franchises, particularly within the immunologicals therapeutic area. This segment, addressing a range of autoimmune and inflammatory conditions such as psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and atopic dermatitis, defied broader industry trends by expanding by an impressive 20.6% even as the overall pharma pipeline contracted. This indicates a robust demand for effective treatments in these chronic conditions and continued innovation in targeted biologics.
Leading this growth were several key players. Sanofi/Regeneron’s Dupixent (dupilumab) demonstrated a strong performance, growing 20.2% to reach $17.736 billion. Dupixent’s broad approvals across atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps have solidified its position as a versatile and highly effective treatment. AbbVie’s Skyrizi (risankizumab) for psoriasis and psoriatic arthritis experienced a substantial 49.9% increase, reaching $17.562 billion, showcasing its rapid market penetration and patient adoption. Its fellow AbbVie product, Rinvoq (upadacitinib), a JAK inhibitor, also posted significant gains, growing 39.1% to $8.304 billion. Johnson & Johnson’s Tremfya (guselkumab), another IL-23 inhibitor for psoriasis and psoriatic arthritis, surged by 40.5% to $5.155 billion. Novartis’s Cosentyx (secukinumab), for similar indications, grew by 8.6% to $6.668 billion.
The success of these immunologicals highlights the ongoing shift towards highly targeted therapies that offer improved efficacy and safety profiles for patients suffering from debilitating chronic inflammatory conditions. Companies in this space continue to invest heavily in expanding indications and developing next-generation biologics, signaling that immunologicals will remain a cornerstone of pharmaceutical growth for the foreseeable future.
Challenges and Declines: The Impact of Patent Expirations and Market Shifts
While innovation drove growth in many areas, FY2025 also saw significant declines for several established pharmaceutical products, primarily due to patent expirations, generic competition, and changing market dynamics. The most striking declines included:
- Stelara (ustekinumab) by J&J: A precipitous drop of 41.3% to $6.078 billion from $10.361 billion. This decline is largely attributable to the emergence of biosimilar competition, particularly in Europe, following patent expirations.
- Humira (adalimumab) by AbbVie: The long-standing blockbuster suffered a massive 49.5% decline to $4.540 billion from $8.993 billion. This was a widely anticipated event, as multiple adalimumab biosimilars entered the U.S. market, eroding Humira’s once-unassailable market share.
- Gardasil (HPV vaccine) by Merck: Experienced a 39.0% decline to $5.233 billion from $8.583 billion. While still a vital public health vaccine, this decrease might reflect market saturation in some regions or specific purchasing patterns in others, though the vaccine remains globally critical.
- Comirnaty (COVID-19 vaccine) by Pfizer/BioNTech: Dropped by 18.4% to $4.367 billion. This decline was expected as the immediate urgency of the pandemic subsided and vaccination rates stabilized, leading to reduced demand for primary vaccination series.
- Paxlovid (COVID-19 antiviral) by Pfizer: Saw the most significant percentage drop among top sellers, plummeting by 58.7% to $2.362 billion. Similar to Comirnaty, reduced incidence of severe COVID-19 and broader population immunity led to a decrease in demand for acute treatment.
- Revlimid (lenalidomide) by BMS: As noted, a 48.9% decrease due to generic entry.
- Sprycel (dasatinib) by BMS: Declined sharply by 61.7% to $493 million, also likely impacted by generic competition.
These declines underscore the cyclical nature of the pharmaceutical industry, where even the most successful drugs eventually face market erosion. Companies must continually innovate and manage their product lifecycles, preparing for these inevitable shifts through robust R&D pipelines and strategic portfolio management. The impact of these patent cliffs often necessitates a re-evaluation of commercial strategies and a renewed focus on emerging growth drivers.
Steady Performers and Emerging Innovators
Amidst the dramatic shifts, several drugs maintained strong, consistent performances or demonstrated significant growth, reflecting their established utility and expanding market presence. In cardiovascular health, BMS/Pfizer’s Eliquis (apixaban) remained a stalwart, growing 8.3% to $14.443 billion. Boehringer Ingelheim/Lilly’s Jardiance (empagliflozin) for diabetes and heart failure also saw a 4.8% increase to $9.932 billion, while AstraZeneca’s Farxiga/Forxiga (dapagliflozin) grew 10.0% to $8.492 billion. These SGLT2 inhibitors continue to demonstrate broad clinical benefits beyond glucose lowering.
Gilead Sciences’ Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), a leading HIV treatment, posted a solid 6.7% increase, reaching $14.300 billion, showcasing its continued importance in managing HIV. In neurology, Roche’s Ocrevus (ocrelizumab) for multiple sclerosis grew by 3.9% to $8.436 billion. Pfizer’s Vyndaqel family (tafamidis) for transthyretin amyloidosis continued its impressive trajectory with a 17.0% increase to $6.380 billion, reflecting growing diagnosis and treatment in a rare disease area. GSK’s Shingrix (zoster vaccine recombinant, adjuvanted) for shingles vaccination maintained steady growth at 5.8%, reaching $4.687 billion.
The list also highlighted a range of newer therapies with promising growth trajectories. BMS’s Reblozyl (luspatercept) for anemia in certain blood disorders grew 31.2% to $2.327 billion. GSK/ViiV’s Cabenuva (cabotegravir/rilpivirine), a long-acting injectable for HIV, soared 38.4% to $1.847 billion, signaling a shift in HIV treatment paradigms towards less frequent dosing. Several recently launched BMS oncology and rare disease drugs like Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab/relatlimab), and Camzyos (mavacamten) also demonstrated significant year-over-year percentage gains, albeit from smaller bases, indicating strong early adoption and potential for future growth.
Methodology and Data Integrity
The FY2025 Pharma 50 ranking is meticulously constructed from primary financial filings reported by the world’s leading pharmaceutical companies. This ensures accuracy and direct reporting of sales figures. For companies reporting in currencies other than the U.S. Dollar (USD), the original figures are preserved alongside the specific IRS conversion rates applied for standardization. For instance, Novo Nordisk’s sales in Danish Krone (DKK) were converted using a rate of 6.617, Sanofi/Regeneron’s in Euros (EUR) at 0.886, Roche’s in Swiss Francs (CHF) at 0.831, and GSK’s in British Pounds (GBP) at 0.759. This rigorous methodology underpins the credibility and reliability of the Pharma 50 analysis, offering a transparent and comprehensive overview of the industry’s commercial performance.
Broader Industry Implications and Future Outlook
The FY2025 Pharma 50 report paints a picture of an industry undergoing profound transformation. The unprecedented success of GLP-1 agonists highlights the immense rewards for companies that address large, unmet medical needs with truly innovative therapies. This success is expected to drive further research and development into chronic diseases with significant public health burdens, such as obesity, diabetes, and cardiovascular conditions.
Conversely, the significant declines of former blockbusters due to patent expirations underscore the relentless pressure on pharmaceutical companies to continuously innovate and diversify their pipelines. This will likely fuel continued merger and acquisition activity as larger firms seek to acquire promising assets from smaller biotechs to shore up their future growth prospects. The robust performance of immunologicals also indicates a sustained market for advanced treatments in autoimmune diseases, prompting ongoing investment in precision medicine and targeted therapies.
Looking ahead, the pharmaceutical industry will continue to navigate complex challenges, including evolving regulatory landscapes, global access and pricing pressures, and the rising costs of R&D. However, the FY2025 data clearly demonstrates that innovation remains the most powerful engine for growth and value creation, promising continued advancements in patient care and significant shifts in market leadership for years to come. The dynamic interplay between groundbreaking science, market demand, and strategic execution will define the next chapter for the global pharmaceutical sector.
Leave a Reply